Debt-to-equity of Gain Therapeutics, Inc. from 30 Sep 2022 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Gain Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2022 to 30 Sep 2025.
  • Gain Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 96%, a 62% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Gain Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 96% +37% +62% 30 Sep 2025
Q2 2025 86% +22% +33% 30 Jun 2025
Q1 2025 69% +4.2% +6.4% 31 Mar 2025
Q4 2024 64% +7.6% +13% 31 Dec 2024
Q3 2024 59% +11% +23% 30 Sep 2024
Q2 2024 65% +29% +81% 30 Jun 2024
Q1 2024 65% +39% +149% 31 Mar 2024
Q4 2023 57% +35% +164% 31 Dec 2023
Q3 2023 48% +31% +175% 30 Sep 2023
Q2 2023 36% 30 Jun 2023
Q1 2023 26% 31 Mar 2023
Q4 2022 21% 31 Dec 2022
Q3 2022 18% 30 Sep 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.